(Alliance News) - AstraZeneca PLC and its partner Sanofi SA on Thursday said nirsevimab, their antibody against respiratory syncytial virus, has been approved for review by the US Food & Drug Administration for preventing RSV lower respiratory tract disease in newborns and infants up to 24 months of age. Read More
(Alliance News) - Stock prices in London were higher at midday on Wednesday, with sentiment remaining upbeat as investors looked to the year-end after the Christmas break. Read More
(Alliance News) - AstraZeneca PLC on Wednesday said it won two new drug approvals in the European Union for Imfinzi and Lynparza to treat cancer. Read More
(Alliance News) - Stock prices in London opened higher on Wednesday, while official statistics showed a surge in UK government borrowing, as Westminster forks out billions for its energy support scheme. Read More
(Alliance News) - AstraZeneca PLC on Monday said it received a host of approvals or recommendations for approval for a handful of prospective treatments in the EU, but noted disappointing phase 3 trial results for Imfinzi. Read More
(Alliance News) - Stock prices in London opened higher on Monday, but the FTSE 100 was lagging behind European counterparts, despite gains for oil and mining stocks. Read More
(Alliance News) - HealthBeacon PLC on Friday said it appointed a new interim chief financial officer, while the process to appoint a CFO on a permanent basis is ongoing. Read More
(Alliance News) - C4X Discovery Holdings PLC on Thursday said its annual loss widened, but it remains positive in its outlook, citing a partner programme with AstraZeneca PLC. Read More
(Alliance News) - AstraZeneca PLC on Thursday alongside US peer Merck & Co, announced that the US Food & Drug Administration will extend the Prescription Drug User Fee Act date by three months to allow further time for a full review of the supplementary new drug application of Lynparza in combination with abiraterone and prednisone or prednisolone. Read More
(Alliance News) - Stock prices in London are set to open lower on Thursday, after the US Federal Reserve raised interest rates as expected and ahead of three more central bank decisions. Read More
(Alliance News) - Daiichi Sankyo Co Ltd on Friday said updated results from a phase 1 trial showed datopotamab deruxtecan continued to show promising responses in patients with breast cancer. Read More
